<DOC>
	<DOCNO>NCT00536731</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety 2 actuation Symbicort®pMDI® 40/2.25 μg twice daily compare with1 inhalation Symbicort Turbuhaler® 80/4.5 μg twice daily 1 inhalation Pulmicort®Turbuhaler® 100 μg twice daily 6 week .</brief_summary>
	<brief_title>Symbicort Rapihaler Therapeutic Equivalence Study</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<criteria>Asthma clinically diagnose since least 6 month . Lung function value measure ≥ 50 % ≤ 90 % predict normal . Patients reversible airway obstruction Daily use inhale steroid ( brand ) &gt; 3 month . Use oral , rectal parenteral steroid within 30 day prior start study . Respiratory infection affect asthma , judge investigator , within 30 day prior start randomise treatment . Any significant disease disorder , opinion investigator , may either put patient risk participation study , may influence result study patient 's ability participate study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Symbicort</keyword>
</DOC>